Source:http://linkedlifedata.com/resource/pubmed/id/17263634
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2007-1-31
|
pubmed:abstractText |
To report the tolerance of indinavir combined with ritonavir (IDV/r 800/100 mg) twice daily (bid) in sub-Saharan African HIV-infected adults. HAART-naives patients started zidovudine plus lamivudine plus IDV/r 800/100 mg bid. Follow-up included standardized documentation of morbidity, CD4(+) cell count, creatininemia, plasma HIV-1 RNA, and IDV minimal plasma concentration (C(min)) measurements at month 1 (M1), M3, and M6. Seventy HIV-1-infected adults (68 women, median CD4 235/mm(3)) started HAART. At M6, 63% had undetectable viral load, and the median gain in CD4 since baseline was +128/mm(3). During the first 6 months, 21 patients experimented with 23 treatment modifications (reduction in IDV/r 400/100 mg bid, n = 11; switch to efavirenz, n = 11; zidovudine replaced by stavudine, n = 1), including 22 for digestive intolerance and 1 for severe anemia. At M1, M3, and M6, 67, 59, and 48 patients were still receiving IDV/r 800/100 mg bid, of whom 70%, 72%, and 60% had IDV Cmin above 5 ng/ml, respectively. In these patients, at M1, M3, and M6, the mean (+/- SD) IDV C(min) were 3431 +/- 3835 ng/ml, 2288 +/- 2116 ng/ml, and 1543 +/- 2398 ng/ml, respectively. There was no renal insufficiency of any grade, and no symptoms of urinary stones. The IDV/r 800/100 mg bid-containing regimen led to high IDV Cmin and a high rate of digestive intolerance. There was a surprising lack of nephrological side effects during the 6 months of follow-up, supporting the hypothesis that nephrological tolerance of IDV might be higher in sub-Saharan African individuals than in Americans or Europeans.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0889-2229
|
pubmed:author |
pubmed-author:AnglaretXavierX,
pubmed-author:AnzianAmaniA,
pubmed-author:BissagneneEmmanuelE,
pubmed-author:DanelChristineC,
pubmed-author:GabillardDelphineD,
pubmed-author:GomisOlivier BaOB,
pubmed-author:MingaAlbertA,
pubmed-author:MohRaoulR,
pubmed-author:NzunettuGustaveG,
pubmed-author:PeytavinGillesG,
pubmed-author:SalamonRogerR,
pubmed-author:SeriBogaB
|
pubmed:issnType |
Print
|
pubmed:volume |
23
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
62-6
|
pubmed:meshHeading |
pubmed-meshheading:17263634-Adult,
pubmed-meshheading:17263634-Cohort Studies,
pubmed-meshheading:17263634-Cote d'Ivoire,
pubmed-meshheading:17263634-Female,
pubmed-meshheading:17263634-Follow-Up Studies,
pubmed-meshheading:17263634-HIV Infections,
pubmed-meshheading:17263634-HIV Protease Inhibitors,
pubmed-meshheading:17263634-HIV-1,
pubmed-meshheading:17263634-HIV-2,
pubmed-meshheading:17263634-Humans,
pubmed-meshheading:17263634-Indinavir,
pubmed-meshheading:17263634-Male,
pubmed-meshheading:17263634-RNA, Viral,
pubmed-meshheading:17263634-Retrospective Studies,
pubmed-meshheading:17263634-Time Factors,
pubmed-meshheading:17263634-Treatment Outcome,
pubmed-meshheading:17263634-Viral Load
|
pubmed:year |
2007
|
pubmed:articleTitle |
Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire.
|
pubmed:affiliation |
Programme PAC-CI, Abidjan, Ccte d'Ivoire.
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|